Foamix starts patient dosing in third phase 3 study of minocycline foam FMX101 in patients with acne

"During a recent Type B Meeting, the FDA confirmed that statistically significant findings from a third study would constitute replication of the Study FX2014-05 results, and would be sufficient to establish an efficacy claim. This confirmation supports our plans for conducting a third Phase 3 study," said David Domzalski, CEO of Foamix. "Initiating this study within four months of the release of the Study 04 and Study 05 results is a direct reflection of the focus and commitment of the entire Foamix team to bring new and innovative solutions to patients."

FX2017-22 is a double-blind, vehicle-controlled, multi-center study that will enroll 1,500 patients with moderate-to-severe acne. This study will be conducted at approximately 80 sites throughout the United States. Patients will be randomized 1:1 to either 4% minocycline foam (FMX101) or vehicle, with once daily treatment for 12 weeks.

The primary endpoints are: 1) the proportion of patients achieving success at week 12 based on an Investigator's Global Assessment (success is defined as a score of "clear" or "almost clear" and at least a 2 category improvement from baseline), and 2) the mean change from baseline in inflammatory lesion counts in each treatment group at week 12. Safety evaluation will include reported adverse events, assessments of tolerability, clinical laboratory tests and vital signs.

As a result of the FDA discussion on the design of a third study, Foamix has decided to maintain the design agreed upon with FDA for Study FX2014-05.

Foamix will continue to run, in parallel, the long-term open-label safety extension to evaluate the safety of intermittent use of FMX101 under Study 04 and Study 05. The open-label safety extension is scheduled to complete by year-end 2017.

Foamix expects to report top-line results from Study FX2017-22 by mid-2018.

Foamix starts patient dosing, minocycline foam fmx101, patients with acne